ABSTRACT Ophthalmia neonatorum, also called neonatal conjunctivitis, acquired during delivery can occur in the first 28?days of life. Commonly caused by the bacterial pathogen Neisseria gonorrhoeae , infection can lead to corneal scarring, perforation of the eye, and blindness. One approach that can be taken to prevent the disease is the use of an ophthalmic prophylaxis, which kills the bacteria on the surface of the eye shortly after birth. Current prophylaxes are based on antibiotic ointments. However, N.?gonorrhoeae is resistant to many antibiotics and alternative treatments must be developed before the condition becomes untreatable. This study focused on developing a fatty acid-based prophylaxis. For this, 37 fatty acids or fatty acid derivatives were screened in vitro for fast antigonococcal activity. Seven candidates were identified as bactericidal at 1?mM. These seven were subjected to irritation testing using three separate methods: the bovine corneal opacity and permeability (BCOP) test; the hen’s egg test—chorioallantoic membrane (HET-CAM); and the red blood cell (RBC) lysis assay. The candidates were also tested in artificial tear fluid to determine whether they were effective in this environment. Four of the candidates remained effective. Among these, two lead candidates, monocaprin and myristoleic acid, displayed the best potential as active compounds in the development of a fatty acid-based prophylaxis for prevention of ophthalmia neonatorum. IMPORTANCE Ophthalmia neonatorum is a painful bacterial infection of the eye in newborns. A common cause is Neisseria gonorrhoeae , which has the potential to cause severe damage to the eye and blindness. This study was designed to identify new and unconventional drug candidates that could be used in an eye ointment to prevent the development of this disease. The drugs that were tested were fatty acid-based compounds. The potential candidates were screened for their ability to kill bacteria in tear fluid without causing damage to the eye. This study identified seven candidates that are fast acting and nonirritating, with two strong candidates for potential use in the eye. Further development and testing are now required to formulate an eye treatment incorporating these drugs to prevent ophthalmia neonatorum.
展开▼